Thursday, September 17, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Researchoral semaglutidetype 2 diabetescardiovascular

Study compares cardiovascular outcomes for oral semaglutide in type 2 diabetes

Diabetes Therapy analysis looks at new users of oral semaglutide versus other noninsulin therapies in patients with atherosclerotic cardiovascular disease.

PR
By Priya Raman · Science Reporter
Sep 16 20:00 ETSource: Diabetes therapy : research, treatment and education of diabetes and related disorders

The wire

  1. 01Researchers compared cardiovascular outcomes among new oral semaglutide users and other noninsulin glucose-lowering drug users.
  2. 02Cohort had type 2 diabetes plus established atherosclerotic cardiovascular disease, a high-risk group.
  3. 03Reported results and magnitude of any difference are not in the excerpt.

From the source

Comparing Cardiovascular Outcomes in New Users of Oral Semaglutide Versus Other Noninsulin Glucose-Lowering Therapies Among Adults with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026 Sep 17 · Tan X, Liang Y, Zhong C et al.

Read at pubmed.ncbi.nlm.nih.gov
Source URL https://pubmed.ncbi.nlm.nih.gov/42753116/